CClinicalTrials.gg
CompletedNCT05620875Updated May 30, 2025

The Association Between Delivered Oxygen and Cerebral Impact During the Use of Cardiopulmonary Bypass.

An observational study in Cardiac; Arteriosclerosis and Aortic Valve Disease, sponsored by Uppsala University. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Uppsala University · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
106
Sex
All
01

Study summary

Investigating the connection between delivered oxygen index and cerebral impact with COx (cerebral oximetry index) och cerebral injury markers during the routine use of cardiopulmonary bypass.

Read the detailed description

The research subjects are to be treated with CPB with according to local standards (perfusion index 2.4 x body surface area). While measuring impact on cerebral autoregulation with the aid of Near InfraRed Spectroscopy (NIRS) and brain injury markers in blood, research subjects depending on initial hemoglobin value, will divide into two subgroups: one with DO2I of >280 ml/min/m2, and one with DO2I of \<280 ml/min/m2.

DO2I will during CPB be calculated using the patient data monitoring system Metavision.

With a correlation analysis between NIRS and MAP (mean arterial pressure) a COx (Cerebral Oxymetry Index) r-value can indicate impact on cerebral autoregulation with values >0.3 - 0.5 during use of CPB 4.

Brain injury markers (Tau, Glial Fibrillary Acidic Protein (GFAP), Neurospecific Enolase (NSE)) are collected during 5 occasions during the first 24 hours and then once per day for 4 days, as well as markers for AKI (S-Creatinine) in some extent.

Registrations during the intensive care regarding delirium, stroke or other neurological impact will also be included in the study.

02

Conditions studied

  • Cardiac; Arteriosclerosis
  • Aortic Valve Disease
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

120 research subjects scheduled for coronary arterial bypass grafting surgery and/or aortic valve replacement in Uppsala University Hospital.

Inclusion criteria

  • Patients scheduled for CABG and/or AVR

Exclusion criteria

Exclusion Criteria:

  • Former diagnosed neurological insults, carotid stenosis
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
106 participants (actual)
Target follow-up
5 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group with DO2i <280 ml/min/m2 during cardiopulmonary bypass

    Diagnostic Test: Cerebral injury markers · Diagnostic Test: Cerebral oximetry index

  • Group with DO2i >280 ml/min/m2 during cardiopulmonary bypass

    Diagnostic Test: Cerebral injury markers · Diagnostic Test: Cerebral oximetry index

Interventions

  • Diagnostic testCerebral injury markers

    Blood tests at given time points perioperatively.

  • Diagnostic testCerebral oximetry index

    Cerebral oximetry index measurements with the aid of Near Infrared Spectroscopy

05

What researchers measure

Primary outcomes

  1. COx

    COx (Cerebral Oximetry Index; correlation between rSO2 values (INVOS) and mean artery pressure) that indicated impact on cerebral autoregulation on DO2 index values below set limits of 280 ml/m2/min.

    Time frame: 24 hours

  2. Brain injury markers; tau, GFAP, NSE

    Brain injury markers that indicate cerebral neuronal damage on DO2 index values below set limits of 280 ml/m2/min.

    Time frame: 96 hours

06

Study locations

1 site
  • Uppsala University Hospital
    Uppsala, 75135, Sweden
07

Registry details

Key details

Study ID
NCT05620875
Lead sponsor
Uppsala University
Collaborators
Uppsala University Hospital
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Jan 2, 2023
Primary completion
Jan 4, 2025
Completion
Jan 4, 2025
Last update
May 30, 2025

Study contacts

Karl-Henrik Grinnemo, Adj. Prof.
principal investigator · Uppsala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion